Related Experiment Video

Updated: Aug 12, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

L Serfaty1, H Aumaître, O Chazouillères

  • 1Service d'Hépato-gastroentérologie, Hôpital St-Antoine, Assistance Publique-Hôpitaux de Paris, France.

Hepatology (Baltimore, Md.)
|May 15, 1998
PubMed

Insights

Interferon therapy significantly improves survival in patients with compensated hepatitis C virus (HCV)-related cirrhosis. Absence of treatment increases the risk of hepatocellular carcinoma (HCC) and decompensation, highlighting the importance of antiviral therapy.

Area of Science:

  • Hepatology and Viral Gastroenterology
  • Oncology and Cancer Research
  • Clinical Medicine and Therapeutics

Background:

  • Hepatitis C virus (HCV)-related cirrhosis, even in compensated stages, carries risks of decompensation, hepatocellular carcinoma (HCC), and mortality.
  • Understanding the impact of viral genotype and interferon (IFN) therapy on the prognosis of compensated HCV cirrhosis is crucial for patient management.

Purpose of the Study:

  • To evaluate the incidence of decompensation, HCC, and liver transplantation or death in patients with compensated HCV cirrhosis.
  • To determine the influence of viral genotype and interferon therapy on the outcomes of these patients.

Main Methods:

  • A cohort of 103 patients with compensated HCV-related cirrhosis was followed for a median of 40 months.
  • Patients' baseline characteristics, HCV genotypes, and treatment with IFN were recorded.
  • Outcomes including cirrhosis complications, HCC development, and survival were assessed using multivariate analysis.

Main Results:

  • The 4-year risk of HCC was 11.5%, and the risk of decompensation was 20%.
  • Absence of IFN therapy was an independent predictor for both HCC and decompensation.
  • IFN-treated patients showed significantly better survival rates (97% at 2 years, 92% at 4 years) compared to untreated patients (95% at 2 years, 63% at 4 years).

Conclusions:

  • Complications of cirrhosis are common in compensated HCV cirrhosis, irrespective of viral genotype.
  • Absence of interferon therapy is a significant independent predictor of poor outcomes, including HCC, decompensation, and mortality.
  • Early antiviral treatment, such as with IFN, is critical for improving survival in patients with compensated HCV cirrhosis.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Related Concept Videos

Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...